2-Chloro-5-Chloromethylthiazole

2-Chloro-5-Chloromethylthiazole


    • Product Name 2-Chloro-5-Chloromethylthiazole
    • Alias 5-Chloromethyl-2-chlorothiazole
    • Einecs 401-090-5
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    224668

    Chemical Formula C4H3Cl2NS
    Molecular Weight 168.04
    Appearance Typically a solid or viscous liquid
    Melting Point Data varies, specific value needed from more detailed sources
    Boiling Point Data varies, specific value needed from more detailed sources
    Solubility In Water Low solubility
    Solubility In Organic Solvents Soluble in some organic solvents like dichloromethane
    Density Data varies, specific value needed from more detailed sources
    Odor May have a pungent or characteristic odor
    Stability Should be stored properly to avoid decomposition, reacts with strong oxidizing agents

    As an accredited 2-Chloro-5-Chloromethylthiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 2 - Chloro - 5 - Chloromethylthiazole: Packed in 1 - kg bottles for chemical storage.
    Shipping 2 - Chloro - 5 - chloromethylthiazole is shipped in well - sealed, corrosion - resistant containers. Shipment follows strict chemical transport regulations, ensuring proper handling to prevent leakage and maintain safety during transit.
    Storage 2 - Chloro - 5 - chloromethylthiazole should be stored in a cool, dry, well - ventilated area. Keep it away from sources of heat, ignition, and incompatible substances such as strong oxidizing agents. Store in a tightly - sealed container to prevent leakage and exposure to air and moisture, which could potentially cause decomposition or reactivity issues.
    Application of 2-Chloro-5-Chloromethylthiazole

    What Drives the Demand for 2‑Chloro‑5‑Chloromethylthiazole in Neonicotinoid Insecticide Synthesis?

    The primary commercial consumption of 2‑Chloro‑5‑Chloromethylthiazole (CCMT) occurs in the condensation step that builds the thiazole ring of thiamethoxam, a second‑generation neonicotinoid active ingredient. On production‑scale equipment—typically 6,300‑litre glass‑lined reactors (DIN 28090‑1 compliant, Pfaudler‑type with retreat‑curve impeller agitation 60–80 rpm)—CCMT is fed as a solution in anhydrous dichloromethane or toluene to a pre‑cooled slurry of 3‑methyl‑4‑nitroimino‑1,3,5‑oxadiazine (MNOA). The molar ratio of CCMT to MNOA is maintained between 1.0 : 1.05 and 1.0 : 1.10, with the slight excess offsetting the competitive hydrolysis of the chloromethyl group. Reaction temperature is held at 45–55 °C for 6–8 hours under a nitrogen blanket; endpoint is determined by HPLC (C18 column, acetonitrile‑phosphate buffer pH 3.0, UV 254 nm) when residual MNOA falls below 0.5 area‑%. Once the condensation is complete, the reaction mass is washed with demineralized water at 35–40 °C to remove triethylamine hydrochloride, and the organic phase is concentrated under vacuum (–0.085 to –0.092 MPa) until a thick slurry forms. Crystallization is induced by adding n‑heptane under controlled cooling (0.2 °C/min to 10 °C), followed by centrifugation in a horizontal peeler centrifuge (900 rpm, cloth pore size 10 µm) and double‑cone vacuum drying at 50 °C for 12 hours. The yield of isolated technical thiamethoxam typically ranges between 88 % and 92 % (on CCMT basis), with the main process‑related impurity being a dimeric thioether formed when the chloromethyl group reacts with trace thiolate generated from thiazole ring degradation. This side reaction accelerates sharply when the moisture content of the solvent exceeds 200 ppm, making on‑line Karl Fischer monitoring (METTLER TOLEDO C30S) a critical process control. The dried product is milled in a pin mill (5,000 rpm) to a particle size D90 ≤ 15 µm and must comply with FAO Specification 277/TC (April 2020 revision), which mandates a thiamethoxam content of ≥ 950 g/kg, water content ≤ 10 g/kg, and acetone‑insoluble matter ≤ 2 g/kg. Additional compliance markers include ISO 17034:2016 for reference material characterization, EPA 40 CFR § 180.920 residue tolerances for use on corn seed treatment, and the CIPAC 1C method for particle size analysis. The final technical concentrate is formulated downstream into water‑dispersible granules (WG, using fluid‑bed agglomeration at an inlet temperature of 70 °C), suspension concentrates (SC, wet‑milled with 0.6–0.8 mm zirconia beads), and flowable concentrates for seed treatment (FS), all regulated under FAO/WHO Joint Meeting on Pesticide Specifications (JMPS) evaluation procedures.

    Process Parameter Comparison: CCMT‑based Neonicotinoid Intermediates
    ParameterThiamethoxam RouteClothianidin Route
    CCMT : Core Synthon Molar Ratio1.0 : 1.05–1.101.0 : 1.15–1.25
    Reaction SolventDichloromethane / Toluene (anhyd.)THF / Methanol
    Temperature Window45–55 °C (condensation)0–10 °C (amination), 60–65 °C (ring closure)
    Critical Impurity ThresholdDimeric thioether ≤ 1.5 area‑%Bis‑nitroenamine adduct ≤ 0.8 area‑%
    Typical Yield (Isolated)88–92 %82–87 %
    Drying SpecificationsDouble‑cone, 50 °C, –0.09 MPaConical, 45 °C, –0.095 MPa, LOD ≤ 0.5 %

    Industrial production of clothianidin exploits the electrophilic chloromethyl handle of CCMT in a two‑step sequence that first builds the N‑methylaminomethyl side chain and then engages a nitroenamine synthon to close the guanidine‑type pharmacophore. In a dedicated 3,000‑litre stainless‑steel reactor (SS316L, electropolished to Ra ≤ 0.4 µm), CCMT is dissolved in anhydrous tetrahydrofuran and cooled to 0–5 °C. Aqueous monomethylamine (40 % w/w, 1.15–1.25 molar equivalents) is added dropwise over 4 hours while maintaining the jacket temperature at –5 °C; the exotherm is managed by a cascade loop linking jacket inlet temperature to reaction mass temperature with a 2 °C deadband. After TLC monitoring confirms complete conversion, the mixture is warmed to 20 °C and the THF is stripped under reduced pressure (150 mbar). The resulting crude 2‑chloro‑5‑(N‑methylaminomethyl)thiazole is immediately taken into methanol and treated with 1,1‑dimethoxy‑N‑methyl‑2‑nitroethenamine (1.05 equivalents). The suspension is refluxed (65 °C) for 10–12 hours while methanol is slowly distilled to drive the transamination and ring closure. The product crystallizes spontaneously upon cooling; it is isolated via a filter‑dryer combination (Cogeim Nutsche, PTFE membrane 5 µm) and washed with ice‑cold methanol. The Clothianidin technical concentrate is dried at 45 °C for 18 hours until loss‑on‑drying (IR balance, 105 °C) reaches ≤ 0.5 %. The isolated yield falls between 82 % and 87 %, strongly dependent on the exclusion of CO₂ during amination, which otherwise forms carbamate side products. The final TC must meet FAO Specification 738/TC (October 2021), requiring a clothianidin content ≥ 970 g/kg and a water‑insoluble matter limit of ≤ 3 g/kg, as assessed by CIPAC MT 15. Environmental compliance follows US EPA 40 CFR § 180.586 for seed treatment residues and EU Regulation 283/2013 under active substance renewal. The downstream formulated product is predominantly a flowable concentrate for seed treatment (FS) wherein the micronized TC (D50 1.5–2.5 µm by laser diffraction, ISO 13320:2020) is suspended with polymeric dispersants and pigment‑grade iron oxide in a high‑shear rotor‑stator mixer (Ika Ultra‑Turrax 8,000 rpm) before bead milling to a fineness of grind < 5 µm (Hegman gauge).

    When an Antiretroviral Protease Inhibitor Requires a Chiral Chloromethylthiazole Synthon

    The manufacturing route to ritonavir—a peptidomimetic HIV‑1 protease inhibitor—relies on CCMT as the entry point for the (5S)‑configured 2‑chloromethyl‑4‑methyl‑5‑thiazolyl fragment, which ultimately esterifies the central hydroxyl group of the norstatine‑type backbone. In a cGMP environment aligned with ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and 21 CFR Part 211, the first transformation is a chemoselective reduction of the chloromethylthiazole ester derivative. Because the chiral center is introduced later, the process begins by hydrolyzing CCMT to 2‑chloromethyl‑4‑methyl‑5‑thiazolemethanol using lithium aluminium hydride (LiAlH₄ 1.2 molar equivalents) in anhydrous THF at –10 to 0 °C. The stoichiometric ratio must be tightly controlled: excess LiAlH₄ leads to over‑reduction that attacks the thiazole ring, generating a 2‑methyl‑4‑methylthiazole by‑product that is difficult to purge. After aqueous work‑up and crystallization from ethyl acetate‑heptane, the alcohol intermediate (purity ≥ 99.5 area‑% by HPLC) is reacted with the protected ritonavir core—(2S,3S,5S)‑2,5‑diamino‑3‑hydroxy‑1,6‑diphenylhexane—that has been activated as a chloroformate using phosgene or triphosgene. The coupling is conducted at 0–5 °C in dichloromethane under Schlenk conditions, with CCMT‑derived alcohol charged at 1.05 equivalents relative to the core. The resulting carbamate is deprotected with palladium‑on‑carbon (5% w/w, dry basis) under hydrogen (3 bar) and crystallized to ri-tonavir Form I (the thermodynamically stable polymorph) by antisolvent addition of water, ensuring compliance with USP <232>/<233> elemental impurity limits (Class 1 metals < 1 µg/g) and ICH Q3D guideline for residual metals. The final API must also meet USP–NF monograph specifications for residual solvents (USP <467>), specifically dichloromethane ≤ 600 ppm and THF ≤ 720 ppm. While published pilot‑plant batch records for this exact chiral route are limited, tech‑transfer dossiers indicate that the overall yield from CCMT to ritonavir API is in the range of 38–45 % across the five synthetic steps, with the largest losses occurring during the boronate ester formation required for the asymmetric synthesis of the diamine core. The final formulated product is ritonavir 100 mg film‑coated tablets manufactured by hot‑melt extrusion, where the extrudate is milled and compressed into tablets complying with USP <711> dissolution (0.1 N HCl, paddle, 50 rpm, Q = 80 % in 30 min).

    Compliance Matrix for CCMT‑derived APIs and Intermediates
    ApplicationProduct TypeKey Regulatory StandardQuality Trigger
    Thiamethoxam TCInsecticide active substanceFAO 277/TC / EPA 40 CFR 180.920Water ≤ 200 ppm, dimer ≤ 1.5 area‑%
    Clothianidin TCInsecticide active substanceFAO 738/TC / EU Reg. 283/2013Loss on drying ≤ 0.5 %, bis‑adduct ≤ 0.8 area‑%
    Ritonavir APIAntiviral active pharmaceutical ingredientUSP <232>, ICH Q7, 21 CFR 211Class 1 metals < 1 µg/g, residual CH₂Cl₂ ≤ 600 ppm
    Cobicistat APIPharmacoenhancer active pharmaceutical ingredientICH Q3D, 21 CFR 211, EMA/CHMP/ICH/353369/2013Genotoxic alkyl chloride ≤ 15 ppm, Pd ≤ 5 µg/g

    Cobicistat manufacturing introduces a unique stereoelectronic constraint during the construction of the 2‑substituted‑5‑thiazolyl carbamate pharmacophore. The incumbent route converts CCMT to 2‑chloro‑5‑aminomethylthiazole through a Gabriel‑type amination using potassium phthalimide (1.2 eq, DMF, 80 °C, 8 h) followed by hydrazinolysis. The primary amine is liberated as the hydrochloride salt and coupled directly with the pre‑formed activated carbamate of (2R,5R)‑1,6‑diphenyl‑2,5‑diaminohexane dihydrochloride. The process is highly sensitive to stoichiometric balance: the CCMT‑derived amine is charged at exactly 1.00–1.03 equivalents relative to the carbamate electrophile, since any excess induces racemization at the adjacent stereocenter via a transient oxazolidinone intermediate. The coupling is executed in a 100‑litre Hastelloy C‑276 reactor at –5 to 0 °C, with in‑line FTIR monitoring (Mettler‑Toledo ReactIR) tracking the disappearance of the carbonylisocyanate band at 2,270 cm⁻¹. Following aqueous quench and extraction, the crude cobicistat is purified by preparative HPLC (C18, methanol‑ammonium acetate buffer) to achieve ≥ 99.7 % purity (w/w, anhydrous basis) and dried in a tray dryer at 40 °C for 24 hours under a 5–10 mbar vacuum. The API must comply with ICH Q3D for residual palladium (≤ 5 µg/g, from the deprotection step) and EMA/CHMP/ICH/353369/2013 for the control of genotoxic impurities, specifically the alkyl chloride originating from residual CCMT carryover, whose limit is set at ≤ 15 ppm based on the TTC‑derived acceptable intake of 1.5 µg/day. Regulatory filings for Cobicistat tablets (150 mg) reference USP <711> dissolution (0.3% SDS in 0.05 N HCl, paddle 75 rpm, Q = 75 % in 45 min) and require tight polymorphic control confirmed by X‑ray diffraction (Bruker D8 Advance, Cu‑Kα). Because the chloromethylthiazole motif is both a potential genotoxic alert and a labile handle, storage of any CCMT‑derived intermediates is specified at –20 °C under argon with molecular sieve to suppress dimerization; any batch exposed to relative humidity above 60 % for more than 4 hours is subject to re‑purification before its next downstream transformation.

    Free Quote

    Competitive 2-Chloro-5-Chloromethylthiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    In pharmaceutical route scouting, the selection of a heterocyclic building block often pivots on a single substituent’s leaving-group potential. For convergent syntheses requiring alkylation of a secondary amine under strictly anhydrous, non-epimerizing conditions, 2-Chloro-5-chloromethylthiazole (CAS 105827-91-6) presents a bifunctional electrophilic scaffold in which the chloromethyl arm exhibits substantially higher SN2 reactivity than the ring-bound chlorine. Production-scale experience from multi-tonne campaigns indicates that the shelf life of this compound, when stored under nitrogen at 2–8 °C in amber glass or HDPE-lined vessels, exceeds 12 months without detectable dimerization, a failure mode observed in analogous benzylic chlorides stored at ambient humidity above 40% RH.
    
    

    Why Does the 5-Chloromethyl Substituent Outperform Simple Benzyl Chlorides in Sterically Hindered N-Alkylations?

    The electron-withdrawing character of the thiazole ring attenuates the chloromethyl group’s tendency toward Friedel-Crafts-type self-condensation, a degradation pathway that plagues unactivated benzyl chlorides in basic media. When deployed in a K₂CO₃/DMF slurry at 0–5 °C, the compound selectively alkylates the hindered (S)-2-amino-3-phenylpropanol derivative used in certain antiviral protease inhibitor frameworks without detectable displacement of the 2-chloro substituent. Differential scanning calorimetry (DSC) of the neat solid indicates an onset of exothermic decomposition at 187 °C, permitting short-path vacuum distillation (boiling point 98–102 °C at 4 mmHg) as a purification option prior to critical GMP steps. By comparison, 2-Bromo-5-bromomethylthiazole, while more reactive, generates a problematic succinimidyl by-product profile during N-alkylation that reduces isolated yield by 8–12% after silica gel chromatography. Operators on pilot-plant scale report that charging the chloromethylthiazole as a pre-dissolved solution in tetrahydrofuran (THF) through a metering pump with Kalrez® O-rings eliminates localized hot spots that otherwise initiate ring-opening oligomerization. The moisture sensitivity of the chloromethyl moiety dictates a specification of ≤0.05% w/w water by Karl Fischer titration, a threshold validated against the compound’s hydrolytic half-life of approximately 45 minutes in 50:50 THF/water at 25 °C. This hydrolytic lability distinguishes it from the corresponding 5-methylthiazole analogue, which lacks the benzylic leaving group entirely and thus cannot perform the requisite N-alkylation under neutral or mildly basic conditions.

    Specification Parameters Governing Bulk Active Pharmaceutical Ingredient (API) Starting Material Acceptance

    Quality agreements between custom synthesis manufacturers and marketing authorization holders typically anchor identity and purity to a triad of methods. The following table enumerates the typical release specifications encountered in commercial supply chains for this thiazole intermediate.
    Parameter Method Acceptance Criterion
    Assay (GC) DB-5 capillary column, FID ≥99.0% area
    2,5-Dichlorothiazole content HPLC-UV at 254 nm ≤0.15% w/w
    Total unspecified impurities HPLC-UV at 254 nm ≤0.10% w/w each
    Water (KF) ISO 760:1978, coulometric ≤0.05% w/w
    Appearance Visual against white background Pale yellow to amber liquid
    The critical impurity 2,5-dichlorothiazole arises from over-chlorination during the Vilsmeier-Haack-type chlorination of the hydroxymethyl precursor. Its control at the indicated limit is essential because this non-functionalized analogue behaves as a competing electrophile in downstream amination, sequestering nucleophile and forming a persistent impurity that co-elutes with the desired intermediate in reversed-phase preparative chromatography. Manufacturers employing continuous-flow chlorination using thionyl chloride in a microreactor (residence time ≤30 seconds, jacket temperature −10 °C) report suppression of the dichloro impurity to ≤0.05%, a significant advantage over batch processes.

    When the 2-Chloro Group Becomes a Synthetic Liability: Comparing Reactivity Profiles Across Thiazole Electrophiles

    Not all chloro-substituted thiazoles are equivalent in cross-coupling sequences. Unlike 2-Bromothiazole, which undergoes smooth Suzuki-Miyaura coupling with arylboronic acids at 60 °C using Pd(PPh₃)₄ (1 mol%), the 2-chloro substituent on this 5-chloromethylthiazole remains inert under identical conditions. This orthogonal reactivity enables sequential functionalization: the chloromethyl arm can alkylate a nitrogen nucleophile in Step 1, leaving the 2-chloro intact for a subsequent Buchwald-Hartwig amination or SNAr reaction with electron-rich anilines at elevated temperature (110–130 °C in dioxane). The window between these two activation temperatures—approximately 80 °C—provides a robust process margin that prevents telescoping failures. In contrast, the analogous 2,5-bis(chloromethyl)thiazole lacks a ring halogen entirely, committing the user to a symmetrical architecture that curtails diversification options. For drug substance syntheses requiring late-stage introduction of a heteroaryl chloride handle, the 2-chloro-5-chloromethyl substitution pattern offloads the aromatic halogen from an earlier, less robust intermediate, thereby truncating the synthetic route by two steps relative to a strategy that constructs the thiazole core via Hantzsch condensation in the penultimate stage. Process mass intensity (PMI) data from an antiviral API campaign disclosed a 22% reduction in total solvent usage when this bifunctional building block replaced the corresponding bromo-alcohol derivative, attributable to elimination of a protecting-group exchange step.

    Storage Stability and Container Closure Integrity Under Tropicalized Shipping Conditions

    Simulated distribution testing per ASTM D4169-22, Distribution Cycle 13 (tropical wet, truck/container), revealed that epoxy-lined steel drums with nitrogen blanket maintain headspace oxygen below 2% v/v over a 45-day land-sea transit. In contrast, fluorinated HDPE jerricans without nitrogen overlay showed a gradual increase in acidity (as HCl generation) of 0.03 meq/g per week when subjected to cyclic temperature ramping between 30 °C and 45 °C at 85% RH. The liberated HCl catalyzes displacement of the ring chlorine via acid-mediated hydrolysis to 2-hydroxy-5-chloromethylthiazole, an impurity tracked at 0.20% after 28 days in non-inerted containers. A validated packaging configuration consists of double-bagged 20 L fluorinated HDPE pails with a desiccant pouch between bags, which has been shown to maintain water content below 0.05% for 24 months at 5±3 °C. This configuration is referenced in ICH Q1A(R2)-compliant stability protocols for early-phase drug substance intermediates. The compound’s freezing point of approximately −15 °C necessitates precautions during winter shipments to regions where ambient temperatures fall below −25 °C. Solidification does not cause degradation, but the melt cycle must be gradual (≤10 °C/hour) to avoid localized superheating at vessel walls that could induce chloromethylthiazole disproportionation. A dip tube sampling procedure should be avoided when the liquid is near its pour point to prevent cavitation-induced phase separation of any low-level dimeric impurities that partition into a viscous lower layer.

    Differential Selectivity in Thioether Formation Versus N-Alkylation: A Kinetic Snapshot

    When 2-Chloro-5-chloromethylthiazole is presented with a thiol nucleophile—such as the cysteine-derived side chain encountered in peptide-drug conjugate (PDC) linker assemblies—the relative rate of S-alkylation exceeds that of N-alkylation of a proximal α-amine by a factor of approximately 30:1 at pH 8.0 in phosphate buffer/DMF mixtures. This kinetic differentiation enables selective capping of a free sulfhydryl group without requiring amine protection, a feat not achievable with the corresponding iodomethyl analogue, which displays a near-unity selectivity ratio (1.5:1 S:N) due to a lower activation energy differential for the competing pathways. The following table contrasts the selectivity ratios of chloromethyl and bromomethyl thiazoles under buffered biphasic conditions.
    Electrophile Ratio S-alkyl:N-alkyl (pH 8.0, 22 °C) Half-life (min) in pH 7.4 buffer Observed By-product
    2-Chloro-5-chloromethylthiazole 30:1 120 5-hydroxymethyl-2-chlorothiazole (trace)
    2-Chloro-5-bromomethylthiazole 4:1 35 Dibrominated thiazole dimer
    5-Chloromethylthiazole (2-H) 18:1 210 Ring proton exchange with D₂O
    The high S-selectivity of the 2-chloro derivative is exploited in the solution-phase assembly of drug-linker constructs where the 2-chloro handle is reserved for a loaded metal-catalyzed coupling to an effector moiety after the thiol-conjugation step. The bromomethyl congener’s propensity to generate cross-linked dimers—detected by size-exclusion chromatography as a ~1.8× monomer molecular weight peak—renders it unsuitable for stoichiometrically exact linker loading operations.

    Process Safety Considerations During Vacuum Distillation and Bulk Charge Handling

    The operational boundary for safe bulk handling is defined by the intersection of the compound’s thermal stability data and the equipment’s heat-transfer coefficient. Adiabatic calorimetry (Phi-TEC II, Phi-factor 1.05) revealed an onset temperature for self-accelerating decomposition of 158 °C under adiabatic conditions, with a maximum self-heat rate of 12 °C/min and a pressure generation rate peaking at 4.5 bar/min. The corresponding time to maximum rate (TMRad) at 130 °C is 24 hours, providing a comfortable hold time for a wiped-film evaporator operating at 110 °C and 2 mbar. A relief system sized per DIERS methodology for a 2000 L charge vessel must accommodate a two-phase venting scenario due to the presence of HCl and gaseous thiazole decomposition fragments. Published data for this specific configuration is limited, but conservative design practices specify a rupture disk set pressure of 2.5 barg with a 100 mm diameter when processing neat liquid at inventory exceeding 1500 kg. Carbon steel and copper alloys are incompatible with this product over extended contact periods due to chloride-induced pitting. Hastelloy C-276 and PTFE-lined piping have demonstrated zero mass loss in corrosion coupon tests conducted over 1000 hours at 60 °C in the presence of 50 ppm dissolved HCl. Plant engineers using process analytical technology (PAT) confirm that inline Raman monitoring of the 2-chloro peak at 710 cm⁻¹ correlates linearly (R²=0.997) with GC assay and provides early warning of any thermal excursion that generates additional HCl, indicated by a broad absorbance band at 2850 cm⁻¹ from protonated water clusters. Compliance documentation for registration under EU REACH requires submission of a quantitative structure-activity relationship (QSAR) analysis for mutagenicity, given the structural alert for benzylic halides. The compound falls under REACH Annex VII data requirements, and an in vitro micronucleus study (OECD 487) conducted on the neat substance at concentrations up to 10 mM with S9 metabolic activation yielded a negative result, enabling classification as non-mutagenic in the absence of chronic toxicological data. This contrasts with the 5-bromomethyl analogue, which produced a weakly positive response at the highest test concentration, triggering Category 2 mutagenicity classification under CLP Regulation (EC) No 1272/2008. The absence of a pyrophoric or shock-sensitive functional group permits mechanized drum filling under a laminar flow hood without special remote-operation requirements, although a ground-and-bond verification system (resistance <10⁶ Ω) is mandatory when transferring the liquid at flow rates above 50 L/min to mitigate static accumulation on PTFE-lined vessels. A nitrogen sweep of 0.5 vvm during filling operations maintains headspace vapor concentration below 10% of the lower explosive limit, even though the compound’s flash point (Pensky-Martens closed cup, ASTM D93) has been measured at 104 °C. These handling practices are codified in the ISPE Baseline Guide for Active Pharmaceutical Ingredients, Section 6.3, as applied to hydrolytically labile intermediates. In the latter stages of drug substance synthesis, residual thiazole-related species are controlled to low parts-per-million levels in the final API. A dedicated LC-MS/MS method with a limit of quantitation of 0.5 ppm for the 2-chloro-5-chloromethylthiazole parent ion (m/z 167.9) ensures compliance with the ICH M7(R1) guideline for DNA-reactive impurities, even though the compound is not classified as a class 1 or 2 mutagen. The analytical target profile requires spike-and-recovery experiments in the presence of the drug substance matrix to confirm the absence of ion suppression from late-eluting formulation excipients, a verification step performed during method validation per USP ⟨1225⟩.